| ■ 영문 제목 : Whole Genome Sequencing Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables, Services), By Type, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MR045
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 2월
■ 페이지수 : 180
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 전게놈 시퀀스 (WGS) 시장 규모가 2023년부터 2030년 사이에 CAGR 20.06% 증가하여, 2030년에는 66.7억 달러에 달할 것으로 전망하고 있습니다. 본 자료는 세계의 전게놈 시퀀스 (WGS) 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 제품별 (기기, 소모품, 서비스) 분석, 종류별 (대규모, 소규모) 분석, 워크 플로우별 (프리 시퀀스, 시퀀스, 데이터 분석) 분석, 용도별 (인간, 식물, 동물, 미생물) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카) 분석, 경쟁 현황 등의 내용을 수록하고 있습니다. 또한 본 리포트는 Illumina, Inc., Thermo Fisher Scientific, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., BGI, QIAGEN, Agilent Technologies, ProPhase Labs, Inc. Nebula Genomics), Psomagen, Azenta US, Inc. (GENEWIZ) 등의 기업 정보가 포함되어 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 전게놈 시퀀스 (WGS) 시장 규모 : 제품별
- 기기의 시장 규모
- 소모품의 시장 규모
- 서비스의 시장 규모
・세계의 전게놈 시퀀스 (WGS) 시장 규모 : 종류별
- 대규모 전게놈 시퀀스 (WGS)의 시장 규모
- 소규모 전게놈 시퀀스 (WGS)의 시장 규모
・세계의 전게놈 시퀀스 (WGS) 시장 규모 : 워크 플로우별
- 프리 시퀀스의 시장 규모
- 시퀀스의 시장 규모
- 데이터 분석의 시장 규모
・세계의 전게놈 시퀀스 (WGS) 시장 규모 : 용도별
- 인간 전게놈 시퀀스 (WGS)의 시장 규모
- 식물 전게놈 시퀀스 (WGS)의 시장 규모
- 동물 전게놈 시퀀스 (WGS)의 시장 규모
- 미생물 전게놈 시퀀스 (WGS)의 시장 규모
・세계의 전게놈 시퀀스 (WGS) 시장 규모 : 지역별
- 북미의 전게놈 시퀀스 (WGS) 시장 규모
- 유럽의 전게놈 시퀀스 (WGS) 시장 규모
- 아시아 태평양의 전게놈 시퀀스 (WGS) 시장 규모
- 중남미의 전게놈 시퀀스 (WGS) 시장 규모
- 중동과 아프리카의 전게놈 시퀀스 (WGS) 시장 규모
・경쟁 현황 |
■ 보고서 개요Whole Genome Sequencing Market Growth & Trends
The global whole genome sequencing market size is projected to reach USD 6.67 billion by 2030, expanding at a CAGR of 20.06% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market growth can be attributed to the rising adoption of whole genome sequencing for genome mapping programs and the increasing prevalence of inherited disorders, including rare genetic disorders. According to the study published in the New England Journal of Medicine in November 2021, whole genome sequencing could lead to the early diagnosis of a wide range of rare diseases and a reported transition to precision medicine.
Furthermore, the growing investment in R&D for the early detection and treatment of disorders with the aid of WGS is expected to propel the growth of the market. For instance, in February 2023, the government of Indonesia and the Genome Science Initiative, with the aid of a USD 30 million investment from the Global Fund, established a network of facilities to perform the method for the early detection and treatment of disorders, including COVID-19, tuberculosis, cancer, genetic disorders, brain diseases, and metabolic disorders.
Whole genome sequencing has a wide range of applications, and government bodies are adopting these technologies for sequencing the genomes of humans, plant, animal, and microbes, which is expected to drive market growth. For instance, U.S. Food & Drug Administration (FDA) adopted the method to identify foodborne pathogens during foodborne disease outbreaks across the countries. The FDA has adopted this technology since 2008 under the Whole Genome Sequencing (WGS) program as it enables it to distinguish all strains of foodborne pathogens more efficiently than pulse-field gel electrophoresis (PFGE).
The rising technological advancements have led to the launch of innovative whole genome sequencing products that offer an affordable, accurate, and timely diagnosis of various diseases and infections. This is contributing to the growth of the market. For instance, in December 2022, LifeCell International Pvt. Ltd. collaborated with HaystackAnalytics to launch TB, a whole genome sequencing test to identify the diagnostic information on tuberculosis infections and tackle the drug resistance challenge.
The COVID-19 pandemic led to an increased demand for the method globally, which enabled the rapid identification of SARS-CoV-2 and the development of possible diagnostic tests to manage the outbreak. Hence, governments across the globe collaborated with research organizations and the corporate sector to use the method to identify and diagnose SARS-CoV-2. Several companies have launched genomic services and rapid solutions for the surveillance of the SARS-CoV-2 virus. For instance, QIAGEN offers the whole genome sequencing services SARS-CoV-2 surveillance for the identification of potent mutants, tracing of possible outbreaks, and advancement of vaccine research and drug development.
Whole Genome Sequencing Market Report Highlights
• Consumables segment held the largest share of 61.56% in 2022, owing to the availability of a wide range of consumables and increased adoption of these products due to the shorter duration of use of these products
• By type, the large whole genome sequencing segment accounted for the largest share of 77.32% in the whole genome sequencing market in 2022. This can be attributed to the growing applications for analyzing cancerous tumors and identifying genetic variations in rare diseases
• By workflow, the sequencing segment held the largest market share of 52.12% in 2022, owing to the growing involvement of major companies and the launch of novel products to boost the adoption of the process
• By application, the human whole genome sequencing segment dominated the market in 2022 with a share of 62.91%. This can be attributed to the growing prevalence of rare inherited disorders and growing investment in R&D for the method to identify possible causative agents of these disorders
• By end-use, the academic & research institutes segment dominated the global market with the largest share of 48.72%. The large share of the segment can be attributed to the growing demand for high-throughput technologies at these facilities to conduct comprehensive research in this field
• North America held the largest market share of 51.34% in 2022. The large share can be attributed to the presence of a well-established healthcare system and pharmaceutical industry in the region, which has created a significant demand for whole genome sequencing for clinical and research purposes
■ 보고서 목차Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Rising prevalence of inherited disorders
3.3.2. Decreasing costs for genetic sequencing
3.3.3. Rising demand for whole genome sequencing for genome mapping programs
3.4. Market Restraint Analysis
3.4.1. Ethical and legal challenges associated with genomic sequencing
3.5. Industry Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. Macroeconomic Analysis
3.6. COVID-19 Impact Analysis
Chapter 4. Whole Genome Sequencing Market: Product Business Analysis
4.1. Whole Genome Sequencing Market: Product Market Share Analysis
4.2. Whole Genome Sequencing Market Estimates & Forecast, By Product (USD Million)
4.3. Instruments
4.3.1. Instruments Market, 2018 – 2030 (USD Million)
4.4. Consumables
4.4.1. Consumables Market, 2018 – 2030 (USD Million)
4.5. Services
4.5.1. Services Market, 2018 – 2030 (USD Million)
Chapter 5. Whole Genome Sequencing Market: Type Business Analysis
5.1. Whole Genome Sequencing Market: Type Market Share Analysis
5.2. Whole Genome Sequencing Market Estimates & Forecast, By Type (USD Million)
5.3. Large Whole Genome Sequencing
5.3.1. Large Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
5.4. Small Whole Genome Sequencing
5.4.1. Small Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
Chapter 6. Whole Genome Sequencing Market: Workflow Business Analysis
6.1. Whole Genome Sequencing Market: Workflow Market Share Analysis
6.2. Whole Genome Sequencing Market Estimates & Forecast, By Workflow (USD Million)
6.3. Pre-Sequencing
6.3.1. Pre-Sequencing Market, 2018 – 2030 (USD Million)
6.4. Sequencing
6.4.1. Sequencing Market, 2018 – 2030 (USD Million)
6.5. Data Analysis
6.5.1. Data Analysis Market, 2018 – 2030 (USD Million)
Chapter 7. Whole Genome Sequencing Market: Application Business Analysis
7.1. Whole Genome Sequencing Market: Application Market Share Analysis
7.2. Whole Genome Sequencing Market Estimates & Forecast, By Application (USD Million)
7.3. Human Whole Genome Sequencing
7.3.1. Human Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
7.4. Plant Whole Exome Sequencing
7.4.1. Plant Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
7.5. Animal Whole Exome Sequencing
7.5.1. Animal Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
7.6. Microbial Whole Exome Sequencing
7.6.1. Microbial Market, 2018 – 2030 (USD Million)
Chapter 8. Whole Genome Sequencing Market: End-Use Business Analysis
8.1. Whole Genome Sequencing Market: End-Use Market Share Analysis
8.2. Whole Genome Sequencing Market Estimates & Forecast, By End-Use (USD Million)
8.3. Academic & Research Institutes
8.3.1. Academic & Research Institutes Market, 2018 – 2030 (USD Million)
8.4. Hospitals & Clinics
8.4.1. Hospitals & Clinics Market, 2018 – 2030 (USD Million)
8.5. Pharmaceutical & Biotechnology Companies
8.5.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
8.6. Others
8.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 9. Whole Genome Sequencing Market: Regional Business Analysis
9.1. Whole Genome Sequencing Market Share By Region, 2022 & 2030
9.2. North America
9.2.1. North America Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. Regulatory Framework
9.2.2.5. Reimbursement Scenario
9.2.2.6. U.S. Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Regulatory Framework
9.2.3.5. Reimbursement Scenario
9.2.3.6. Canada Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3. Europe
9.3.1. Europe Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.2. Germany
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Competitive Scenario
9.3.2.4. Regulatory Framework
9.3.2.5. Reimbursement Scenario
9.3.2.6. Germany Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.3. U.K.
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Regulatory Framework
9.3.3.5. Reimbursement Scenario
9.3.3.6. U.K. Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. Regulatory Framework
9.3.4.5. Reimbursement Scenario
9.3.4.6. France Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Regulatory Framework
9.3.5.5. Reimbursement Scenario
9.3.5.6. Italy Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Regulatory Framework
9.3.6.5. Reimbursement Scenario
9.3.6.6. Spain Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Regulatory Framework
9.3.7.5. Reimbursement Scenario
9.3.7.6. Denmark Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Regulatory Framework
9.3.8.5. Reimbursement Scenario
9.3.8.6. Sweden Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Regulatory Framework
9.3.9.5. Reimbursement Scenario
9.3.9.6. Norway Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Competitive Scenario
9.4.2.4. Regulatory Framework
9.4.2.5. Reimbursement Scenario
9.4.2.6. Japan Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. Regulatory Framework
9.4.3.5. Reimbursement Scenario
9.4.3.6. China Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. Regulatory Framework
9.4.4.5. Reimbursement Scenario
9.4.4.6. India Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4.5. South Korea
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Regulatory Framework
9.4.5.5. Reimbursement Scenario
9.4.5.6. South Korea Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Regulatory Framework
9.4.6.5. Reimbursement Scenario
9.4.6.6. Australia Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. Regulatory Framework
9.4.7.5. Reimbursement Scenario
9.4.7.6. Thailand Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.5. Latin America
9.5.1. Latin America Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Competitive Scenario
9.5.2.4. Regulatory Framework
9.5.2.5. Reimbursement Scenario
9.5.2.6. Brazil Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Regulatory Framework
9.5.3.5. Reimbursement Scenario
9.5.3.6. Mexico Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Regulatory Framework
9.5.4.5. Reimbursement Scenario
9.5.4.6. Argentina Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.6. MEA
9.6.1. MEA Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Competitive Scenario
9.6.2.4. Regulatory Framework
9.6.2.5. Reimbursement Scenario
9.6.2.6. South Africa Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Regulatory Framework
9.6.3.5. Reimbursement Scenario
9.6.3.6. Saudi Arabia Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. Regulatory Framework
9.6.4.5. Reimbursement Scenario
9.6.4.6. UAE Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Regulatory Framework
9.6.5.5. Reimbursement Scenario
9.6.5.6. Kuwait Whole Genome Sequencing Market, 2018 – 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Company Market Share Analysis, 2022
10.3. Strategy Mapping
10.4. Company Profiles/Listing
10.4.1. Illumina, Inc.
10.4.1.1. Overview
10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Thermo Fisher Scientific, Inc.
10.4.2.1. Overview
10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Oxford Nanopore Technologies
10.4.3.1. Overview
10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. Pacific Biosciences of California, Inc.
10.4.4.1. Overview
10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. BGI
10.4.5.1. Overview
10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. QIAGEN
10.4.6.1. Overview
10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. Agilent Technologies
10.4.7.1. Overview
10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. ProPhase Labs, Inc. (Nebula Genomics)
10.4.8.1. Overview
10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. Psomagen
10.4.9.1. Overview
10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. Azenta US, Inc. (GENEWIZ)
10.4.10.1. Overview
10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives
|
| ※본 조사보고서 [세계의 전게놈 시퀀스 (WGS) 시장 (2023~2030) : 기기, 소모품, 서비스] (코드 : GRV23MR045) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 전게놈 시퀀스 (WGS) 시장 (2023~2030) : 기기, 소모품, 서비스] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
